Prescription drug · ANDA
Dihydroergotamine mesylate NDC 73352-096
Dihydroergotamine mesylate 4 mg/mL · Spray · Nasal · Trifluent Pharma, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73352-096-19 | 73352009619 | 8 KIT in 1 KIT (73352-096-19) / 1 VIAL, GLASS in 1 KIT (73352-096-18) / 1 mL in 1 VIAL, GLASSMarketed from Jul 8, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Dihydroergotamine mesylate
- Generic name (nonproprietary)
- dihydroergotamine mesylate
- Active ingredients
- Dihydroergotamine mesylate — 4 mg/mL
- Dosage form
- Spray
- Route
- Nasal
- Labeler
- Trifluent Pharma, LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 216881
- Marketing start
- Listing expires
- Other FDA classes
- Ergotamines (Chemical structure)
- Identifiers
- Product ID 73352-096_400914da-88c2-d003-e063-6394a90ad430SPL ID 400914da-88c2-d003-e063-6394a90ad430SPL set ID 4cb78f66-6ccf-4ac7-8599-e199f6995f05RxCUI 861668UNII 81AXN7R2QT
- Pharmacologic class
- Ergotamine Derivative
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N473352009619followed by a unit qualifier and the quantityPackage 73352-0096-19. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 216881
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Dihydroergotamine mesylate | Dihydroergotamine mesylate 4 mg/mL | SprayNasal | Advagen Pharma Ltd | 72888-096 |